Schizophrenia News and Research

Latest Schizophrenia News and Research

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

Adherence to suicide risk assessment urged for schizophrenia patients

Many patients with schizophrenia who attempt suicide after hospital discharge missed out on a pre-discharge suicide risk assessment, shows a study from Denmark. .

8 Nov 2013

Brain & Behavior Research Foundation announces recipients of NARSAD Investigator Grants

The Brain & Behavior Research Foundation (formerly known as NARSAD, the National Alliance for Research on Schizophrenia and Depression), under the direction of Dr. Jeffrey Borenstein, President & CEO, has announced the latest recipients of its NARSAD Distinguished Investigator Grants.

8 Nov 2013

Schizophrenia patients fare well with outpatient care

Study findings corroborate that patients with schizophrenia who receive outpatient care only during the early stages of their illness have better outcomes than those requiring inpatient hospitalization.

7 Nov 2013

Population genetic studies may have limited role in schizophrenia

Studying the genetics of people in the general population who have psychotic experiences is unlikely to yield useful information about schizophrenia, say researchers.

6 Nov 2013

Lack of neurocognitive gender differences in early psychosis

Impairments in neurocognition do not occur at a higher rate in males than in females at the onset of psychosis, suggest findings published in Progress in Neuro-Psychopharmacology and Biological Psychiatry.

5 Nov 2013

Metacognitive training complements antipsychotic therapy

Metacognitive training may benefit patients with schizophrenia who only partially respond to antipsychotic treatment, study findings show.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Offspring born to stressed mothers show stress-induced changes

Children of survivors of extremely stressful life events face adjustment challenges of their own, as has been most carefully studied among the children of Nazi Death Camp survivors. This "intergenerational" transmission of stress response has been studied predominately from the psychological perspective. However, recent research points to biological contributions as well.

5 Nov 2013

Janssen Pharmaceuticals to pay over $1.6 billion in drug misbranding case

On behalf of the U.S. Food and Drug Administration, the U.S. Department of Justice today announced a guilty plea agreement with Janssen Pharmaceuticals, Inc., of Titusville, N.J., and a $400 million criminal fine for introducing a misbranded drug, Risperdal (risperidone), into interstate commerce.

5 Nov 2013

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.

4 Nov 2013

Scientists find surprising degree of variation among genomes of individual neurons

It was once thought that each cell in a person's body possesses the same DNA code and that the particular way the genome is read imparts cell function and defines the individual. For many cell types in our bodies, however, that is an oversimplification.

4 Nov 2013

Self-harm warns of repeated suicide attempt risk in schizophrenia

Individuals who have attempted suicide and also have a history of self-harm should be thoroughly assessed for psychotic symptoms in order to prevent delayed treatment and the risk for repeated suicide attempts, say researchers.

31 Oct 2013

Large, rare CNV burden reduced in bipolar disorder

Large and rare chromosomal copy number variants are uncommon in patients with bipolar disorder, even those with early-onset disease, study findings confirm.

31 Oct 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

Left-handers more likely to suffer from psychotic disorders

Researchers have long studied the connections between hand dominance and different aspects of the human brain. A new study out today in SAGE Open finds that among those with mental illnesses, left-handers are more likely to suffer from psychotic disorders such as schizophrenia than mood disorders.

31 Oct 2013